Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients
January 02, 2013 06:00 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH
December 10, 2012 12:12 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals to Present at Oppenheimer Healthcare Conference
December 05, 2012 06:00 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda
December 04, 2012 06:00 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH
November 20, 2012 06:00 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals to Present at Lazard Healthcare Conference
November 07, 2012 06:00 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals to Present at EORTC-NCI-AACR
October 31, 2012 06:00 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals Reports 2012 Third Quarter Financial Results
October 30, 2012 16:00 ET
|
Astex Pharmaceuticals, Inc.
Dacogen Approved in the European Union for the Treatment of Elderly AML
Initiated HSP90 Inhibitor AT13387 Clinical Trials in Prostate & Lung Cancer Patients
Initiated SGI-110 Clinical Trial...
Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance
October 29, 2012 09:59 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif. and CAMBRIDGE, U.K., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small...
Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer
October 24, 2012 06:00 ET
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 24, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...